-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 DYbdhn+mvAwQ74jGfZ03VxVpDqEv/U+CbsFjHanuY3eclsKQHosvFhhOXVo4Yxiv
 uxhWzyZ+188Cra6Di4GquQ==

<SEC-DOCUMENT>0001102624-04-000143.txt : 20041019
<SEC-HEADER>0001102624-04-000143.hdr.sgml : 20041019
<ACCEPTANCE-DATETIME>20041019094646
ACCESSION NUMBER:		0001102624-04-000143
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20041019
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20041019
DATE AS OF CHANGE:		20041019

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			IMMUCELL CORP /DE/
		CENTRAL INDEX KEY:			0000811641
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				010382980
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-12934
		FILM NUMBER:		041084348

	BUSINESS ADDRESS:	
		STREET 1:		56 EVERGREEN DR
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
		BUSINESS PHONE:		2078782770

	MAIL ADDRESS:	
		STREET 1:		56 EVERGREEN DRIVE
		CITY:			PORTLAND
		STATE:			ME
		ZIP:			04103
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>immucell8k.htm
<DESCRIPTION>IMMUCELL 8K
<TEXT>
<table cellpadding="3" border="0" cellspacing="0" width="100%">
<tr><td>
</td></tr>
</table>
<center>
<table border=0 cellpadding=3 cellspacing=0>
<tr><td align="center"><br><br>
<B>UNITED STATES</B><br>
<B>SECURITIES AND EXCHANGE COMMISSION</B><br>
Washington, D.C. 20549<p>
<hr size=1>
<p><b>FORM 8-K<p>
CURRENT REPORT
<p>
Pursuant to Section 13 or 15(d) of the<br>Securities Exchange Act of 1934.
</td>
</tr>
</table>
<p>
<b>
<table border=0 cellpadding=0 cellspacing=0>
<tr><td colspan=5 align=center>
<b>Date of Report: October   19, 2004</b><br>
(Date of earliest event reported)<br><br>
</td></tr>
<tr><td colspan=5 align=center>
<b>ImmuCell Corporation</b><br>
(Exact name of registrant as specified in its charter)
</td></tr>
<tr>
<td align=center width="20%">
<b>DE</b><br>
(State or other jurisdiction of incorporation)
</td>
<td width="20%">
&nbsp;
</td>
<td align=center width="20%">
<b>0-15507</b><br>
(Commission File Number)
</td>
<td width="20%">
&nbsp;
</td>
<td align=center width="20%">
<b>01-0382980</b><br>
(IRS Employer Indentification Number)
</td>
</tr>
<tr>
<td width="20%">
&nbsp;
</td>
<td align=center width="20%" colspan=2>
<b>56 Evergreen Drive, Portland, ME</b><br>
(Address of principal executive offices)
</td>
<td align=center width="20%" colspan=2>
<b>04103</b><br>
(Zip Code)
</td>
<td width="20%">
&nbsp;
</td>
</tr>
<tr><td colspan=5 align=center>
<br>Registrant's telephone number, including area code: <b>(207) 878-2770</b>
</td></tr>
</table>
</center>
<hr size=1>
<table width=100%>
<tr><td width="100%">
<b>Item 2.02. Results of Operations and Financial Condition</b></b><br>
<br>
On October 19, 2004, ImmuCell Corporation (the "Company") issued a press release announcing earnings results for the three and nine month periods ended September 30, 2004. The full text of the press release issued in connection with the announcement is attached as Exhibit 99.1 to this Current Report on Form 8-K.
<p>
The information shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act (the "Exchange Act") or otherwise subject to liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 of the Exchange Act, except as expressly set forth by specific reference in such filing.
<p>
<b>Item 9.01. Financial Statements and Exhibits</b></b><br>
<p>
(a) Not Applicable<br>
(b) Not Applicable<br>
(c) Exhibits<br>
<br>
<p>
99.1 &nbsp; &nbsp; &nbsp; <a href="immucellcorporation.htm">Press Release of ImmuCell Corporation dated October   19, 2004</a></b>
<p>
<p>
<hr size=1>
<b><center>SIGNATURE</center></b>
<p>
&nbsp; &nbsp; &nbsp; Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
              signed on its behalf by the undersigned hereunto duly authorized.<p>
</td></tr>
</table>
<table>
<tr>
<td width="50%" valign=top>
Dated: October   19, 2004<br>
</td>
<td>
<b>IMMUCELL CORPORATION</b>
<p>
By: <u>&nbsp;/s/ Michael F. Brigham &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; </u> <br>
&nbsp; &nbsp; &nbsp;Michael F. Brigham<br>
&nbsp; &nbsp; &nbsp;<i>President/CEO</i><br>
</td></tr>
</table>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1 CHARTER
<SEQUENCE>2
<FILENAME>immucellcorporation.htm
<DESCRIPTION>IMMUCELL PRESS RELEASE
<TEXT>

<p></p>
<b>ImmuCell Announces Sales Growth and Other Financial Results for Three and Nine Months Ended September 30, 2004</b>
<p>PORTLAND, ME -- 10/19/2004 --  ImmuCell Corporation (NASDAQ: ICCC) today
announced the results of its operations for the three and nine month
periods ended September 30, 2004.
</p>
<p>
For the three months ended September 30, 2004, product sales increased by
8%, or $63,000, to $808,000, in comparison to the same period in 2003.  For
the nine months ended September 30, 2004, product sales increased by 14%,
or $317,000, to $2,668,000, in comparison to the same period in 2003.
</p>
<p>
"Our core business is experiencing steady sales growth, with expected
seasonal fluctuations," commented Michael F. Brigham, president and CEO,
"while we continue to fund the development of Mast Out&#174;."
</p>
<p>
The Company recognized a net loss of $(5,000) for the three months ended
September 30, 2004, compared to a net loss of $(38,000), or $(0.01) per
share, during the same period in 2003.  For the nine months ended September
30, 2004, the Company recognized income before income taxes of $190,000.
This compared with income before income taxes of $920,000 for the same
period in 2003, which included $1,100,000 in other income from the sale of
the Company's interest in a non-core joint venture.  Net income of
$109,000, or $0.04 per diluted share, was recognized for the nine months
ended September 30, 2004, compared to net income of  $539,000, or $0.19 per
diluted share, for the same period in 2003.
</p>
<p>
During the three month period ended September 30, 2004, research and
development expenses increased by 1%, or $3,000, to $272,000, comprising
32% of total revenues in 2004.  During the nine month period ended
September 30, 2004, research and development expenses decreased by 16%, or
$138,000, to $735,000, comprising 27% of total revenues in 2004.  The
primary focus of the Company's research and development efforts continues
to be Mast Out, its Nisin-based treatment for mastitis in lactating dairy
cows.
</p>
<p>
The Company's cash and short-term investments decreased by $4,000, to
$4,241,000 at September 30, 2004, as compared to $4,245,000 at December 31,
2003.  Stockholders' equity increased by 2%, or $145,000, to $7,515,000 at
September 30, 2004, as compared to $7,370,000 at December 31, 2003.
</p>
<p>
ImmuCell Corporation is a biotechnology company that is developing products
intended to help reduce the overuse of antibiotics in animal and human
healthcare and is manufacturing and selling other products that improve
animal health and productivity in the dairy and beef industries.  ImmuCell
Corporation press releases and other information about the Company are
available at its corporate web site at http://www.immucell.com.
<pre>

                                    (Unaudited)             (Unaudited)
                                Three Months Ended       Nine Months Ended
                                   September 30,           September 30,
(In thousands, except per share   2004       2003         2004       2003
amounts)                        -------    -------      -------    -------
Revenues:
Product sales                   $   808    $   745      $ 2,668    $ 2,350
Other revenues                       38         43           85        183
                                -------    -------      -------    -------
Total revenues                      846        788        2,753      2,533

Cost and expenses:
Product costs                       343        335        1,102      1,044
Research and development
 expenses                           272        270          735        874
Selling, general and
 administrative expenses            251        253          767        829
                                -------    -------      -------    -------
Total costs and expenses            866        858        2,604      2,747
                                -------    -------      -------    -------

Net operating (loss) income         (20)       (70)         149       (214)

Interest and other income            15         12           41      1,134
                                -------    -------      -------    -------

(Loss) income before income
 taxes                               (5)       (58)         190        920
Income tax expense (benefit)          -        (20)          81        381
                                -------    -------      -------    -------
Net (loss) income               $    (5)   $   (38)     $   109    $   539
                                =======    =======      =======    =======

Net (loss) income per
 common share:
Basic                           $ (0.00)   $ (0.01)     $  0.04    $  0.20
Diluted                         $ (0.00)   $ (0.01)     $  0.04    $  0.19

Weighted average common
 shares outstanding:
Basic                             2,758      2,741        2,753      2,737
Diluted                           2,758      2,741        2,957      2,813


                                       (Unaudited)
                                     At September 30,    At December 31,
                                           2004               2003
                                         -------            -------
(In thousands)
Cash and short-term investments          $ 4,241            $ 4,245
Total assets                               8,177              8,187
Net working capital                        5,119              4,965
Stockholders' equity                     $ 7,515            $ 7,370
</pre>

</p>
<pre>
Contact:
Michael F. Brigham
President and Chief Executive Officer
(207) 878-2770 Ext. 3106


</pre>

</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
